MGC Pharmaceuticals (ASX:MXC) - CEO and Managing Director, Roby Zomer
CEO and Managing Director, Roby Zomer
Source: MGC Pharmaceuticals
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MGC Pharmaceuticals (MXC) completes the construction phase of the CimetrA production facility in Malta on schedule
  • The company says the facility will have the capacity to produce over 20,000 units of CimetrA in liquid dose form per day – double what was originally planned
  • MGC Pharma received a €3.1 million (around A$4.8 million) cash grant from the Maltese Government to fund the majority of construction costs of the facility
  • An official ribbon cutting ceremony will be taking place on November 16th, following equipment fit out and commissioning
  • MGC Pharmaceuticals was up 4.26 per cent, trading at 4.9 cents at 12:40 pm AEDT

MGC Pharmaceuticals (MXC) said it has completed the construction phase of the CimetrA production facility in Malta on schedule.

MGC Pharma received a €3.1 million (around A$4.8 million) cash grant from the Maltese Government through Malta Enterprise to fund the majority of the costs of construction and equipment fit out of the facility.

The company said the facility will have the capacity to produce over 20,000 units of CimetrA in liquid dose form per day – double what was originally planned.

An official ribbon cutting ceremony will be taking place on November 16th, witnessed by representatives of MGC Pharma, Malta Enterprise and the Maltese Government.

The ceremony will mark the culmination of almost a year’s worth of efforts since the company was awarded a grant by the Maltese Government to build and extend the clinical research facility, originally intended to produce 10,000 units of liquid dose units per day of the COVID-19 anti-inflammatory product, ArtemiC.

Roby Zomer, Co-founder and Managing Director of MGC Pharma, said the completion of the facility provides the company with flexible production capacity, including production of its proprietary treatment for the symptoms of COVID-19.

Equipment fit out will begin immediately, with commissioning set to be completed on schedule.

MGC Pharmaceuticals was up 4.26 per cent, trading at 4.9 cents at 12:40 pm AEDT.    

MXC by the numbers
More From The Market Online

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…

Little Green Pharma closely eyeing USA’s legal downgrade of Cannabis danger

Overnight, the Biden government did something sure to give their counterparts a stir – the USA…

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…